Mental Disorder Or Mental Illness (e.g., Psychoses, Etc.) Affecting Patents (Class 514/17.5)
  • Patent number: 10369189
    Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase C?1 (PLC?1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLC?1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: August 6, 2019
    Assignee: Duke University
    Inventors: James O. McNamara, Xiao-Ping He, Yangzhong Huang, Bin Gu
  • Patent number: 10259843
    Abstract: Cyclic tetrapeptide stereochemical isomers of CJ-15,208, pharmaceutical compositions from such cyclic tetrapeptides, and methods of using such pharmaceutical compositions. The cyclic tetrapeptide compounds and pharmaceutical compositions disclosed herein are potent analgesics active in several pain models with generally minimal tolerance and reduced likelihood to induce addiction relative to other known opiates.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 16, 2019
    Assignee: University of Kansas
    Inventors: Jane V. Aldrich, S P Sanjeewa Nilendra Senadheera
  • Patent number: 10221213
    Abstract: The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: March 5, 2019
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 10098925
    Abstract: The present invention relates to a protein comprising SEQ ID NO:1 (mature form of SLURP-1) and to a composition comprising the same for use in inducing or accelerating cicatrization, and/or in preventing infection in the eye of a subject.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: October 16, 2018
    Assignee: Brightpulse Holding Ltd.
    Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie, Sebastien Mouz, Julien Perino
  • Patent number: 9950033
    Abstract: The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: April 24, 2018
    Assignees: Centre National de la Recherche Scientifique, College de France
    Inventors: Alain Prochiantz, Kenneth Moya, Rajiv Joshi
  • Patent number: 9908972
    Abstract: The present invention provides a photodegradable cross-linking agent capable of manufacturing a photodegradable gel, which has appropriate moisture content and water solubility as a cell carrier and has strength that makes it possible to construct a complicated three-dimensional microstructure. The photodegradable cross-linking agent of the present invention includes a main chain 2 which is composed of branched polyethylene glycol having three or more branched chains and a photodegradable benzyl group 3 which is disposed on the terminus of the branched chains, in which the benzyl group has an active ester group 4, which is reactive with an amino group or a hydroxyl group, and one or more nitro groups in a benzene ring.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: March 6, 2018
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Shinji Sugiura, Toshiyuki Takagi, Fumiki Yanagawa, Kimio Sumaru, Toshiyuki Kanamori
  • Patent number: 9629890
    Abstract: The present invention relates to a composition comprising a tryptophan-containing peptide and having a Trp/LNAA ratio of more than 0.1 for decreasing eating or appetite during or after stress.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: April 25, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Cindy Gerhardt, Joris Kloek, Rob Markus
  • Patent number: 9198973
    Abstract: The present invention is directed to a polymeric compound with a size in a nanometric scale, useful as a biocompatible carrier for the transport and delivery of active agents into a fish, insect, animal, reptile, bird, human, or plant, wherein said polymeric compound comprises PAMAM (polyamidoamine) dendrimers, a spacer molecule, and cafestol, wherein the polymeric compound of the invention comprises a structure of the kind (cafestol-PAMAM derivative)2-spacer molecule. Use of the compound as a biocompatible carrier for transport and delivery of antithrombotic active agents is disclosed. Procedures for obtaining a polymeric compound comprising the activation of cafestol, activation of polyethylene glycol, and formation of cafestol-PAMAM-PEG-PAMAM-cafestol are also disclosed.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: December 1, 2015
    Assignees: Fundacion Fraunhofer Chile Research, Universidad de Talca
    Inventors: Leonardo S. Santos, John Amalraj, Esteban F. Duran Lara, Fabiane M. Nachtigall
  • Publication number: 20150140046
    Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 21, 2015
    Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
  • Publication number: 20150126455
    Abstract: The present invention pertains to novel uses of endomorphine-1 peptide, analogs, and salts thereof for therapy of children, patients currently suffering from drug addiction, patients prone to opioid addiction, and patients with chemo-induced pain.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 7, 2015
    Inventor: Theodore E. Maione
  • Patent number: 9012407
    Abstract: Compositions and methods that act on Neuropeptide S receptors (NPSR) (also known as “TGR23” or “vasopressin receptor-related receptor 1 (VRR1)”) to cause desired effects in the bodies of human or animal subjects. Neuropeptide S (NPS) and other agonists of the NPSR may be administered to cause arousal, awakening, alertness, spontaneous movement, bronchoconstriction, contraction of bronchial smooth muscle or other effects. Antagonists of the NPSR may be administered to cause decreased arousal, decreased awakening, decreased alertness, decreased spontaneous movement, sleep, somnolence, sedation, anxiolytic effects, normalized sleep patterns, normalized sleep stages, increased duration of sleep, bronchodilation, relaxation of broncheal smooth muscle or other effects.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: April 21, 2015
    Assignee: The Regents of the University of California
    Inventors: Olivier Civelli, Rainer K. Reinscheid, Yanling Xu
  • Patent number: 8987206
    Abstract: The present invention relates to a method of treating attention deficit hyperactivity disorder (ADHD) and attention deficit disorder (ADD) by administration of activated-potentiate form of antibodies to brain-specific protein S-100 and activated-potentiate form of antibodies to endothelial NO synthase.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: March 24, 2015
    Inventor: Oleg Iliich Epshtein
  • Patent number: 8969295
    Abstract: The present invention provides methods for identifying genes and pathways involved in plasticity. The invention applies some of these methods to identify genes that are differentially regulated in at least a portion of the nervous system of an individual subjected to conditions known to result in altered nervous system plasticity, i.e., dark rearing (DR) or monocular deprivation (MD). The genes are targets for pharmacological agents that modify plasticity. The invention also identifies biological pathways that are enriched in genes that are differentially regulated under conditions known to result in altered nervous system plasticity. The present invention further provides methods and compositions for modifying plasticity in the nervous system of a subject.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: March 3, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Mriganka Sur, Daniela Tropea, Gabriel Kreiman
  • Publication number: 20150057231
    Abstract: The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons
    Type: Application
    Filed: February 29, 2012
    Publication date: February 26, 2015
    Applicants: COLLEGE DE FRANCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Alain Prochiantz, Kenneth Moya, Rajiv Joshi
  • Publication number: 20150051151
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov
  • Patent number: 8951968
    Abstract: The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: February 10, 2015
    Assignee: Northwestern University
    Inventor: Joseph Moskal
  • Patent number: 8946164
    Abstract: The present invention provides a pharmaceutical or a food that comprises, as an active ingredient, at least one peptide selected from the group consisting of Val-Tyr-Leu-Pro-Arg (SEQ ID NO:1), Tyr-Leu-Pro-Arg (SEQ ID NO:2), and Leu-Pro-Arg (SEQ ID NO:3), or an analog thereof.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: February 3, 2015
    Assignee: Kyoto University
    Inventors: Kousaku Ohinata, Ayako Oda
  • Patent number: 8940700
    Abstract: The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: January 27, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health
    Inventors: John M. Hallenbeck, Hideaki Wakita
  • Publication number: 20150023949
    Abstract: Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 22, 2015
    Inventors: Niven Rajin Narain, Paula Patricia Narain
  • Publication number: 20150004165
    Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.
    Type: Application
    Filed: September 8, 2014
    Publication date: January 1, 2015
    Applicant: INCYTE CORPORATION
    Inventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J.A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
  • Patent number: 8920819
    Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: December 30, 2014
    Assignee: University College London
    Inventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
  • Patent number: 8921306
    Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogs which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: December 30, 2014
    Assignee: The University of Queensland
    Inventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
  • Patent number: 8916524
    Abstract: The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, X-Pro-Pro-Y or a salt thereof, wherein X represent Val, Ile or Asn-Ile and Y represent Phe or Leu.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: December 23, 2014
    Assignee: Calpis Co., Ltd.
    Inventors: Kazuhito Ohsawa, Naoto Uchida, Kohji Ohki
  • Patent number: 8895512
    Abstract: The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, Phe-Pro.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: November 25, 2014
    Assignee: Calpis Co., Ltd.
    Inventors: Kazuhito Ohsawa, Naoto Uchida, Kohji Ohki
  • Patent number: 8895511
    Abstract: The present invention embraces methods for the diagnosis and treatment of learning or mental disorders, as well as the identification of agents useful in the treatment of such disorders based upon the identified involvement of Sarcoplasmic Ca2+-ATPase type 2 Protein in synaptic plasticity and neurotransmitter release in 22q11 deletion/DiGeorge Syndrome.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: November 25, 2014
    Assignee: St. Jude Children's Research Hospital
    Inventor: Stanislav S. Zakharenko
  • Publication number: 20140342991
    Abstract: The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, X-Pro-Pro-Y or a salt thereof, wherein X represent Val, Ile or Asn-Ile and Y represent Phe or Leu.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Inventors: Kazuhito OHSAWA, Naoto UCHIDA, Kohji OHKI
  • Publication number: 20140323408
    Abstract: Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications for reducing dopaminergic cell death.
    Type: Application
    Filed: May 7, 2014
    Publication date: October 30, 2014
    Applicant: PROTEOSYS AG
    Inventor: André SCHRATTENHOLZ
  • Patent number: 8865219
    Abstract: The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO?), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: October 21, 2014
    Assignee: Ethypharm
    Inventors: Mahendra B. Chaudhari, Edouard Gendrot
  • Publication number: 20140294851
    Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.
    Type: Application
    Filed: April 1, 2013
    Publication date: October 2, 2014
    Inventor: MARK QUANG NGUYEN
  • Patent number: 8841254
    Abstract: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: September 23, 2014
    Assignee: Howard Florey Institute of Experimental Physiology and Medicine
    Inventors: Geoffrey Tregear, Ross Alexander David Bathgate, Chrishan Surendran Samuel, Tanya Christine Burazin, Andrew Lawrence Gundlach, John Desmond Wade
  • Publication number: 20140271945
    Abstract: A method of detecting the presence or absence of a disease in a patient wherein said disease is accompanied by deficient levels of S-adenosylmethionine comprising: identifying a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of S-adenosylmethionine in said biological sample using an antibody derived from a hapten analog of S-adenosylmethionine; and correlating the level of S-adenosylmethionine in said biological sample with the presence or absence of said disease. The invention also provides methods for measuring SAH which is used to determine the methylation index (ratio of SAM/SAH) in biological fluids which is indicative of the health status of an individual.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Inventors: Xiujuan Hao, Isaac A. Angres
  • Publication number: 20140274906
    Abstract: The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: NoNO Inc.
    Inventors: Michael Tymianski, Rongwen Li, Jonathan David Garman
  • Patent number: 8815261
    Abstract: [Summary] An external preparation formulation superior in the transdermal absorbability has been desired as a new administration route of aripiprazole. Transdermal absorption of aripiprazole has been enabled for the first time by appropriately combining aripiprazole and an organic acid (particularly fatty acid with low lipophilicity). That is, it has been found that more superior transdermal absorbability can be achieved by forming a salt by using a compound showing lipophilicity within the range of ?1.5-2, such as fatty acid and the like. It has been further found that the transdermal absorbability is remarkable improved by appropriately selecting the solvent composition. As a result, since a new dosage form of aripiprazole other than oral preparation has been developed, a new transdermal absorption preparation of aripiprazole can be provided.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: August 26, 2014
    Assignee: MEDRx Co., Ltd.
    Inventor: Noritaka Hanma
  • Patent number: 8815233
    Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: August 26, 2014
    Assignee: Curemark LLC
    Inventor: Joan M. Fallon
  • Publication number: 20140235546
    Abstract: The 5-HT 2C receptor is implicated in feeding, obesity, palatable food reward, metabolic disorders, drug addiction, anxiety, stress sensitivity, and depression. Embodiments of the invention are directed to modulation of the 5 -HT 2cR. Certain aspects are directed to therapies for the above referenced conditions. In certain aspects, therapeutic agents are identified that disrupt the 5-HT2cR:PTEN complex activating 5-HT2CR signaling. In certain aspects the complex is disrupted by a disrupter. The disrupter can be a peptide that displaces PTEN from the 5-HT 2cR:PTEN complex or inhibits the formation of the complex.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 21, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Kathryn Cunningham, Scott Gilbertson
  • Patent number: 8809278
    Abstract: Cyclic tetrapeptides that are kappa opioid receptor (KOR) antagonists can be used in therapeutic applications for treating, inhibiting, and/or preventing drug addiction, drug use, or drug seeking behavior in a subject. This can include subjects that have a history of drug addiction. The drug can be selected from cocaine, alcohol, amphetamines, methamphetamines, nicotine, opiate, or combinations thereof. These cyclic tetrapeptides can also be useful for treating, inhibiting, and/or preventing stress-induced drug seeking behavior.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: August 19, 2014
    Assignee: University of Kansas
    Inventors: Jane V. Aldrich, Nicolette C. Ross, Santosh Kulkarni
  • Patent number: 8802088
    Abstract: The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: August 12, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Cinderalla C. Gerhardt, Luppo Edens
  • Patent number: 8796214
    Abstract: The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Down syndrome.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: August 5, 2014
    Assignee: Research Foundation For Mental Hygiene, Inc.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 8791076
    Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: July 29, 2014
    Inventors: Pablo Villoslada, Angel Messeguer
  • Patent number: 8772242
    Abstract: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhea, chronic idiopathic nausea, IBD-associated constipation and diarrhea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: July 8, 2014
    Inventor: Thomas Julius Borody
  • Publication number: 20140178307
    Abstract: Methods and assays are disclosed for treating subjects with 22q13 deletion syndrome or SHANK3 deletion or duplication, mutation or reduced expression, where the methods comprise administering to the subject insulin-like growth factor 1 (IGF-1), IGF-1-derived peptide or analog, growth hormone, an AMPAkine, a compound that directly or indirectly enhances glutamate neurotransmission, including by inhibiting inhibitory (most typically GABA) transmission, or an agent that activates the growth hormone receptor or the insulin-like growth factor 1 (IGF-1) receptor, or a downstream signaling pathway thereof.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: Mount Sinai School of Medicine
    Inventors: Joseph D. Buxbaum, Takeshi Sakurai, Ozlem Gunal
  • Publication number: 20140179613
    Abstract: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.
    Type: Application
    Filed: February 5, 2014
    Publication date: June 26, 2014
    Inventors: K. Ulrich BAYER, Steve Coultrap
  • Patent number: 8741847
    Abstract: A method for treating an autism spectrum condition includes administering an effective dose of a TNF-? inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum. A TNF-? inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: June 3, 2014
    Inventor: Michael Chez
  • Publication number: 20140147491
    Abstract: This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder—Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.
    Type: Application
    Filed: January 27, 2012
    Publication date: May 29, 2014
    Inventors: Larry Glass, Michael John Bickerdike, Michael Frederick Snape
  • Publication number: 20140142033
    Abstract: Analogues of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Application
    Filed: December 14, 2011
    Publication date: May 22, 2014
    Applicant: Isotechnika Pharma Inc.
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • Patent number: 8716228
    Abstract: Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide thereof for the treatment of schizophrenia.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: May 6, 2014
    Assignee: YEDA Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Gil M Lewitus, Michal Cardon-Yaakov, Noga Ron-Harel
  • Publication number: 20140107037
    Abstract: The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a NMDA receptor glycine site partial agonist.
    Type: Application
    Filed: April 27, 2012
    Publication date: April 17, 2014
    Inventor: Joseph Moskal
  • Patent number: 8691767
    Abstract: Method for treatment and/or prophylaxis of schizophrenia and related psychoses of a human being, erythropoietin being administered to the human being.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: April 8, 2014
    Inventor: Hannelore Ehrenreich
  • Publication number: 20140073562
    Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.
    Type: Application
    Filed: March 15, 2012
    Publication date: March 13, 2014
    Applicant: OPTINOSE AS
    Inventor: Per Gisle Djupesland
  • Publication number: 20140011730
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Application
    Filed: September 12, 2013
    Publication date: January 9, 2014
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Daniel B. DEOLIVEIRA, Jeanne Mary COMSTOCK